Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway

Oncogenic activation of the KRAS gene via point mutations occurs in 20–30% of patients with non-small cell lung cancer (NSCLC). The RAS-RAF-ERK and RAS-PI3K-AKT pathways are the major hyper-activated downstream pathways in RAS mutation, which promotes the unlimited lifecycle of cancer cells and thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Huanling, Wang, Yuwei, Duan, Fugang, Li, Ying, Jiang, Zebo, Luo, Lianxiang, Liu, Liang, Leung, Elaine L. H., Yao, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113384/
https://www.ncbi.nlm.nih.gov/pubmed/30186180
http://dx.doi.org/10.3389/fphar.2018.00958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113384/
https://www.ncbi.nlm.nih.gov/pubmed/30186180
http://dx.doi.org/10.3389/fphar.2018.00958

Ejemplares similares